Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nintedanib - Boehringer Ingelheim

Drug Profile

Nintedanib - Boehringer Ingelheim

Alternative Names: BIBF-1120; CYNEDIV; Intedanib; OFEV; Ofev; Vargatef

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Atrium Health; Boehringer Ingelheim; Duke University; European Organisation for Research and Treatment of Cancer; Lurie Cancer Center; M. D. Anderson Cancer Center; National Cancer Institute (USA); Northwestern University; Roswell Park Cancer Institute; University College London; University of Alabama at Birmingham; University of Duisburg-Essen
  • Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Skin disorder therapies; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Lyn protein-tyrosine kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Src-Family kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Systemic scleroderma; Idiopathic pulmonary fibrosis; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis; Interstitial lung diseases; Non-small cell lung cancer; Systemic scleroderma
  • Phase III Colorectal cancer; Malignant-mesothelioma; Ovarian cancer; Pulmonary fibrosis
  • Phase II Bladder cancer; Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Inflammatory breast cancer; Liver cancer; Peritoneal cancer; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I/II Malignant melanoma
  • No development reported Multiple myeloma; Salivary gland cancer; Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 07 May 2024 Boehringer Ingelheim completes a phase III trial for Interstitial lung disease (PO) in China (NCT05065190)
  • 12 Apr 2024 Boehringer Ingelheim completes a phase II trial in Lung disorders in USA (NCT02496585)
  • 10 Nov 2023 Updated efficacy data from the phase III SENSCIS-ON trial in Systemic scleroderma presented at the ACR Convergence 2023 (ACR-ARP-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top